Summary & Overview
CPT 0572U: Telomere Length FISH Test for Prostate Cancer Risk
CPT code 0572U designates a proprietary laboratory analysis (PLA) for ProsTAV®, a specific telomere-length test from Life Length S.L. The assay measures cellular telomere length using fluorescence in situ hybridization (FISH) on a blood sample and applies a diagnostic algorithm to report a prostate cancer risk level. As a PLA code, 0572U is unique to a single manufacturer's test and identifies a distinct molecular diagnostic service in claims and reimbursement workflows.
Nationally, PLA codes matter because they signal manufacturer-specific tests with discrete clinical claims handling and price transparency implications. This review addresses major payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare to summarize how the code is recognized across commercial and federal programs.
Readers will learn the clinical scope and service setting for 0572U, the role of the test in prostate cancer risk assessment, and the payer landscape covered in the analysis. The publication also summarizes available benchmarks, relevant policy or coverage considerations, and practical coding and billing context for submitting claims for this proprietary laboratory test. Data not available in the input for specific coverage decisions, reimbursement rates, or associated ICD-10 codes is noted where applicable.
Billing Code Overview
CPT code 0572U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to a single, manufacturer-specific laboratory test: ProsTAV® from Life Length S.L. The test uses a blood sample and measures telomere length in cells using fluorescence in situ hybridization (FISH). Results are processed by a diagnostic algorithm and reported as a risk level for prostate cancer.
Service type: Proprietary laboratory diagnostic test (telomere length analysis with algorithmic risk reporting)
Typical site of service: Clinical laboratory or independent diagnostic testing facility (blood draw performed in an outpatient clinic or phlebotomy site, analysis performed in the sending laboratory)
Clinical & Coding Specifications
Clinical Context
A typical patient is a man aged 50–75 with elevated prostate-specific antigen (PSA) levels, prior atypical prostate biopsy, or other clinical concern for prostate cancer seeking additional risk stratification. The clinician orders the ProsTAV® telomere-length assay (0572U) as an adjunctive laboratory test to refine prostate cancer risk assessment. A phlebotomy appointment is scheduled at an outpatient laboratory or an ambulatory infusion/diagnostic center. A blood sample is collected, labeled with the patient and order identifiers, and shipped per the manufacturer's instructions to Life Length S.L. or its designated laboratory. The laboratory performs fluorescence in situ hybridization (FISH) on peripheral blood cells to measure telomere length, analyzes data using the proprietary diagnostic algorithm, and reports a risk level for prostate cancer (e.g., low, intermediate, high). Results are transmitted to the ordering urologist or primary care clinician who incorporates the assay result into shared decision-making about further diagnostic steps (repeat biopsy, MRI, active surveillance, or definitive therapy). Typical sites of service include outpatient laboratory draw stations, ambulatory surgical centers for patients already undergoing urologic workup, and physician offices with phlebotomy services. Common modifiers for billing include 22 (increased procedural services), 52 (reduced services), and 53 (discontinued procedure).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when additional work or documentation beyond the routine for the test is required and clearly documented (e.g., extensive medical record review or complex medical necessity justification). |
52 | Reduced services | Use when the test is partially reduced or not completed as billed but still performed (for example, limited specimen or partial analysis).
53 | Discontinued procedure | Use when the test collection or processing was started but then discontinued for patient safety or technical reasons prior to completion.
59 | Distinct procedural service | Use when billing this proprietary lab test in conjunction with another service that is separate and distinct (ensure clinical documentation supports distinctness).
76 | Repeat procedure by same provider | Use when the same lab test is repeated by the same provider on the same day due to specimen or processing issues.
77 | Repeat procedure by another provider | Use when the test is repeated by a different provider/lab on the same day.
90 | Reference (Outside) Laboratory | Use when the performing laboratory is independent and the ordering provider is billing only for the professional interpretation or coordination (check payer rules for PLA codes).
91 | Repeat clinical diagnostic laboratory test | Use when a repeat measurement is performed on the same day to confirm prior result.
AO | Worker’s compensation related (State or Federal) | Use when patient encounter is related to workers’ compensation billing requirements.
RT | Right side | Generally not applicable to this blood-based assay but included when laterality reporting is required by payer policies for related procedures.
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207Q00000X | Urology | Ordering clinicians for prostate cancer risk assessment and management. |
208800000X | Hematology & Oncology | Specialists who may order telomere length assays in cancer risk evaluation or research contexts.
207L00000X | Diagnostic Radiology | Radiologists coordinating imaging-guided biopsy decisions informed by risk stratification.
363A00000X | Clinical Laboratory | Laboratory directors and pathologists overseeing specimen processing and test validation.
207R00000X | Family Medicine | Primary care clinicians ordering adjunctive risk stratification tests during prostate cancer evaluation.
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
N40.0 | Enlarged prostate with lower urinary tract symptoms | Common condition prompting prostate evaluation including PSA and adjunctive risk tests like 0572U. |
R97.20 | Elevated prostate specific antigen [PSA], unspecified | Elevated PSA often triggers further risk stratification with tests such as the ProsTAV® telomere-length assay.
C61 | Malignant neoplasm of prostate | Primary diagnosis under evaluation or monitoring where telomere-length risk assessment may inform management decisions.
D07.5 | Carcinoma in situ of prostate | Pre-invasive neoplastic conditions for which additional risk stratification tests may be considered in select clinical contexts.
Z85.46 | Personal history of malignant neoplasm of prostate | History of prostate cancer where surveillance and secondary risk assessment may include adjunctive laboratory assays.
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
0572U | ProsTAV® telomere-length assay (Proprietary Laboratory Analyses) | This is the specific PLA code for the telomere FISH assay and is the billed test when ProsTAV® is performed. |
36415 | Collection of venous blood by venipuncture | Commonly performed immediately prior to 0572U for specimen collection and billing of phlebotomy when separately reportable.
80299 | Unlisted chemistry procedure | Occasionally used when reporting ancillary or investigational chemistry services not otherwise specified alongside a PLA; payer-specific rules apply.
88384 | Immunohistochemistry or special staining, for single or multiple antibody stains | Related in workflows where tissue-based ancillary tests are also performed for prostate biopsy specimens, complementary to blood-based risk assays.
84153 | Prostate specific antigen (PSA) | Commonly obtained in the same clinical workup for prostate cancer risk stratification; complements the telomere-length assay result.